Hi all,
Here is an abstract about Revlimid and treatment-related cytopenia (especially significant declines in platelet count).
Patients with lower-risk MDS patients who have a 5q deletion more often will be transfusion independent if they react with declines in platelet counts.
These findings support the hypothesis that Revlimid has a direct cytotoxic effect on the del(5q) clone, and that the observation of this effect may be indicative of a transfusion independence response.
http://www.oncologystat.com/journals...Syndromes.html
Kind regards
Birgitta-A